MedKoo Cat#: 128016 | Name: GSK1059865
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK1059865 is a selective orexin 1 receptor antagonist that significantly reduces ethanol consumption in ethanol-dependent mice in a dose-dependent manner. The compound did not affect sucrose intake, suggesting its specific action on alcohol dependence rather than general reward-seeking behaviors. The study highlights the potential of targeting orexin signaling for treating addiction disorders such as alcoholism.

Chemical Structure

GSK1059865
GSK1059865
CAS#1191044-58-2

Theoretical Analysis

MedKoo Cat#: 128016

Name: GSK1059865

CAS#: 1191044-58-2

Chemical Formula: C20H23BrFN3O2

Exact Mass: 435.0958

Molecular Weight: 436.33

Elemental Analysis: C, 55.06; H, 5.31; Br, 18.31; F, 4.35; N, 9.63; O, 7.33

Price and Availability

Size Price Availability Quantity
25mg USD 550.00 2 Weeks
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
1g USD 5,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
GSK1059865; GSK 1059865; GSK-1059865
IUPAC/Chemical Name
((2S,5S)-2-(((5-bromopyridin-2-yl)amino)methyl)-5-methylpiperidin-1-yl)(3-fluoro-2-methoxyphenyl)methanone
InChi Key
TWCRHJLMMAYSTE-ZFWWWQNUSA-N
InChi Code
InChI=1S/C20H23BrFN3O2/c1-13-6-8-15(11-24-18-9-7-14(21)10-23-18)25(12-13)20(26)16-4-3-5-17(22)19(16)27-2/h3-5,7,9-10,13,15H,6,8,11-12H2,1-2H3,(H,23,24)/t13-,15-/m0/s1
SMILES Code
O=C(N1[C@H](CNC2=NC=C(Br)C=C2)CC[C@H](C)C1)C3=CC=CC(F)=C3OC
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
GSK1059865 specifically targets the orexin 1 receptor (OX1R), acting as a potent and selective antagonist. This compound was shown to reduce ethanol drinking behavior in ethanol-dependent mice, indicating its potential for modulating addiction-related behaviors through orexin signaling. The selectivity of GSK1059865 suggests that it might be useful in treating alcohol dependence without significantly affecting other reward-seeking behaviors.
In vitro activity:
In vitro, GSK1059865 is a potent, selective antagonist of the orexin 1 receptor (OX1R). It binds to the receptor with high affinity and inhibits orexin A-induced calcium mobilization, which is a key signaling pathway. This bioactivity supports its potential for modulating behaviors linked to addiction, particularly alcohol dependence.
In vivo activity:
In vivo, GSK1059865 significantly reduces ethanol consumption in ethanol-dependent mice in a dose-dependent manner. Notably, it does not affect the intake of non-alcoholic substances like sucrose, indicating its specificity in targeting alcohol-related behaviors. This suggests its potential as a treatment for alcohol dependence without interfering with general reward-seeking behaviors.

Preparing Stock Solutions

The following data is based on the product molecular weight 436.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lopez MF, Moorman DE, Aston-Jones G, Becker HC. The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res. 2016 Apr 1;1636:74-80. doi: 10.1016/j.brainres.2016.01.049. Epub 2016 Feb 4. PMID: 26851547; PMCID: PMC4808605. 2: Merlo Pich E, Melotto S. Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use. Front Neurosci. 2014 Feb 13;8:26. doi: 10.3389/fnins.2014.00026. PMID: 24592206; PMCID: PMC3923148. 3: Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, Corsi M, Bifone A. Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One. 2011 Jan 28;6(1):e16406. doi: 10.1371/journal.pone.0016406. PMID: 21307957; PMCID: PMC3030585. 4: Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, Merlo-Pich E, Di Fabio R, Corsi M. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 2012 Aug;37(9):1999-2011. doi: 10.1038/npp.2012.48. Epub 2012 May 9. PMID: 22569505; PMCID: PMC3398727. 5: Gozzi A, Lepore S, Vicentini E, Merlo-Pich E, Bifone A. Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine. Neuropsychopharmacology. 2013 Oct;38(11):2120-30. doi: 10.1038/npp.2013.109. Epub 2013 May 8. PMID: 23736277; PMCID: PMC3773661.